Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus

被引：74
作者：
Bays, Harold [1 ]
机构：
[1] L MARC, 3288 Illinois Ave, Louisville, KY 40213 USA
来源：
DIABETES THERAPY | 2013年 / 4卷 / 02期
关键词：
Anti-hyperglycemic agents; Efficacy; Glucose homeostasis; Hyperglycemia; Renal function; Safety; Sodium glucose cotransporter type 2 inhibitors; Type 2 diabetes mellitus; PROXIMAL TUBULAR CELLS; CANAGLIFLOZIN CANA; DOUBLE-BLIND; BODY-WEIGHT; ADD-ON; MICROVASCULAR COMPLICATIONS; DAPAGLIFLOZIN MONOTHERAPY; CARDIOVASCULAR OUTCOMES; JAPANESE PATIENTS; METABOLIC MEMORY;
D O I：
10.1007/s13300-013-0042-y
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Although hyperglycemia is a key therapeutic focus in the management of patients with type 2 diabetes mellitus (T2DM), many patients experience sub-optimal glycemic control. Current glucose-lowering agents involve the targeting of various body organs. Sodium glucose co-transporter type 2 (SGLT2) inhibitors target the kidney, reduce renal glucose reabsorption, and increase urinary glucose elimination, thus lowering glucose blood levels. This review examines some of the key efficacy and safety data from clinical trials of the main SGLT2 inhibitors approved or currently in development, and provides a rationale for the use of SGLT2 inhibitors in the treatment of T2DM.
引用
收藏
页码：195 / 220
页数：26
相关论文
共 107 条
[31]   Phlorizin: a review [J].
Ehrenkranz, JRL ;
Lewis, NG ;
Kahn, CR ;
Roth, J .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2005, 21 (01) :31-38
[32]   Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia [J].
El-Osta, Assam ;
Brasacchio, Daniella ;
Yao, Dachun ;
Pocai, Alessandro ;
Jones, Peter L. ;
Roeder, Robert G. ;
Cooper, Mark E. ;
Brownlee, Michael .
JOURNAL OF EXPERIMENTAL MEDICINE, 2008, 205 (10) :2409-2417
[33]   A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes [J].
Ferrannini, E. ;
Seman, L. ;
Seewaldt-Becker, E. ;
Hantel, S. ;
Pinnetti, S. ;
Woerle, H. J. .
DIABETES OBESITY & METABOLISM, 2013, 15 (08) :721-728
[34]   Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise A randomized, double-blind, placebo-controlled, phase 3 trial [J].
Ferrannini, Ele ;
Jimenez Ramos, Silvia ;
Salsali, Afshin ;
Tang, Weihua ;
List, James F. .
DIABETES CARE, 2010, 33 (10) :2217-2224
[35]   Effects of SGLT2 inhibitors on cardiovascular outcomes [J].
Foote, Celine ;
Perkovic, Vlado ;
Neal, Bruce .
DIABETES & VASCULAR DISEASE RESEARCH, 2012, 9 (02) :117-123
[36]  
Forst T, 2013, DIABETES, V62, pA284
[37]   Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: A series of retrospective analyses of data from 1998 through 2002 [J].
Fox, KM ;
Gerber, RA ;
Bolinder, B ;
Chen, J ;
Kumar, S .
CLINICAL THERAPEUTICS, 2006, 28 (03) :388-395
[38]   Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications [J].
Gerich, J. E. .
DIABETIC MEDICINE, 2010, 27 (02) :136-142
[39]   Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management [J].
Grant, Richard ;
Adams, Alyce S. ;
Trinacty, Connie Mah ;
Zhang, Fang ;
Kleinman, Ken ;
Soumerai, Stephen B. ;
Meigs, James B. ;
Ross-Degnan, Dennis .
DIABETES CARE, 2007, 30 (04) :807-812
[40]   Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes A 24-week, randomized, double-blind, placebo-controlled trial [J].
Haering, Hans-Ulrich ;
Merker, Ludwig ;
Seewaldt-Becker, Elke ;
Weimer, Marc ;
Meinicke, Thomas ;
Woerle, Hans J. ;
Broedl, Uli C. .
DIABETES CARE, 2013, 36 (11) :3396-3404
12345678910